Sara Nochur
Direktor/Vorstandsmitglied bei MARINUS PHARMACEUTICALS, INC.
Vermögen: 9 017 $ am 30.04.2024
Aktive Positionen von Sara Nochur
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.01.2021 | - |
| General Counsel | 01.01.2006 | 01.01.2021 | |
| MARINUS PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 22.03.2021 | - |
| Independent Dir/Board Member | 22.03.2021 | - | |
| Hospitality Homes | Vorsitzender | 01.01.2021 | - |
| Biomedical Sciences Careers Program, Inc. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Sara Nochur
Ehemalige bekannte Positionen von Sara Nochur
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| DECIBEL THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 06.12.2021 | 22.09.2023 |
| Independent Dir/Board Member | 06.12.2021 | 22.09.2023 | |
| THE MEDICINES COMPANY | General Counsel | - | - |
| Biotrack, Inc. | Geschäftsführer | - | - |
| General Counsel | - | - | |
| DynaGen, Inc. | Corporate Officer/Principal | - | - |
Ischemix, Inc.
 Ischemix, Inc. Pharmaceuticals: MajorHealth Technology Ischemix, Inc. is a privately-held drug development company based in an undisclosed location. The American company focuses on developing its family of cytoprotective compounds for serious diseases and conditions, with the primary focus being the development of its lead compound, CMX-2043, for the treatment of TBI. Ischemix is working to advance cytoprotective therapies. The company was founded in 1999 by Victor Shashoua, and David DeWahl has been the CEO of the company since 2013. | General Counsel | - | - |
Ausbildung von Sara Nochur
| University of Mumbai | Graduate Degree |
| Massachusetts Institute of Technology | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 11 |
| Indien | 2 |
Operativ
| General Counsel | 4 |
| Director/Board Member | 3 |
| Corporate Officer/Principal | 2 |
Sektoral
| Health Technology | 7 |
| Consumer Services | 2 |
| Finance | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| ALNYLAM PHARMACEUTICALS, INC. | Health Technology |
| MARINUS PHARMACEUTICALS, INC. | Health Technology |
| DECIBEL THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 6 |
|---|---|
Ischemix, Inc.
Ischemix, Inc. Pharmaceuticals: MajorHealth Technology Ischemix, Inc. is a privately-held drug development company based in an undisclosed location. The American company focuses on developing its family of cytoprotective compounds for serious diseases and conditions, with the primary focus being the development of its lead compound, CMX-2043, for the treatment of TBI. Ischemix is working to advance cytoprotective therapies. The company was founded in 1999 by Victor Shashoua, and David DeWahl has been the CEO of the company since 2013. | Health Technology |
| Biotrack, Inc. | |
| DynaGen, Inc. | Health Technology |
The Medicines Co.
 The Medicines Co. Pharmaceuticals: MajorHealth Technology The Medicines Co. is a biopharmaceutical company, which focuses on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on acute and intensive care hospitals worldwide. The firm markets its brands Angiomax, Cleviprex, injectable emulsion, Ionsys, Kengreal, Minocin for injection, and Orbactiv. The company was founded by Clive A. Meanwell, Helmut Giersiefen, John W. Villiger and T. Scott Johnson on July 31, 1996 and is headquartered in Parsippany, NJ. | Health Technology |
| Hospitality Homes | |
| Biomedical Sciences Careers Program, Inc. |
- Börse
- Insiders
- Sara Nochur
- Erfahrung
